8.2. site recurrence. 8.2.1. local recurrence local recurrence takes place soft tissues original surgical site lns. contemporary cystectomy 5–15% probability pelvic recurrence usually occurs first 24 months, often within 6 18 months surgery. however, late recurrences occur five years rc. risk factors described pathological stage, lns, positive margins, extent lnd peri-operative chemotherapy . patients generally poor prognosis pelvic recurrence. even treatment, median survival ranges four eight months following diagnosis. definitive therapy prolong survival, mostly provides significant palliation symptoms. trimodality management generally involves combination chemotherapy, radiation surgery . 8.2.2. distant recurrence distant recurrence seen 50% patients treated rc mibc. local recurrence, pathological stage nodal involvement risk factors . systemic recurrence common locally-advanced disease (pt3/4), ranging 32 62%, patients ln involvement (range 52–70%) . likely sites distant recurrence lns, lungs, liver bone. nearly 90% distant recurrences appear within first three years rc, mainly first two years, although late recurrence described 10 years. median survival patients progressive disease treated platinum-based chemotherapy 9–26 months [580-582]. however, longer survival (28–33% 5 years) reported patients minimal metastatic disease undergoing tmt management, including metastasectomy . 8.2.3. urothelial recurrences rc, incidence new urethral tumours 4.4% (1.3–13.7%). risk factors secondary urethral tumours urethral malignancy prostatic urethra/prostate (in men) bladder neck (in women). orthotopic neobladder associated significant lower risk urethral tumours rc (or: 0.44) . limited data, agreement, urethral follow-up, authors recommending routine surveillance urethral wash urine cytology others doubting need routine urethral surveillance. however, significant survival advantage men urethral recurrence diagnosed asymptomatically vs. symptomatically, follow-up male urethra indicated patients risk urethral recurrence . treatment influenced local stage grade urethral occurrence. urethral cis, bcg instillations success rates 83% . invasive disease, urethrectomy performed urethra site disease; case distant disease, systemic chemotherapy indicated . upper urinary tract ucs occur 4–10% cases represent common sites late recurrence (3-year dfs following rc) . median os 10–55 months, 60–67% patients die metastatic disease . meta-analysis found 38% utuc recurrence diagnosed follow-up investigations, whereas remaining 62%, diagnosis based symptoms. urine cytology used surveillance, rate primary detection 7% vs. 29.6% uut imaging. meta-analysis concluded patients non-invasive cancer twice likely utuc patients invasive disease . multifocality increases risk recurrence three-fold, positive ureteral urethral margins increase risk seven-fold. radical nephroureterectomy prolong survival .